ArticleNature immunology2020
Ptpn6 inhibits caspase-8- and Ripk3/Mlkl-dependent inflammation.
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Integrated identification of key immune related genes and patterns of immune infiltration in calcified aortic valvular disease: A network based meta-analysis.Frontiers in genetics · 2022Pooled it
- Redundant γc cytokines license IL-1-driven neutrophil inflammation through MEK/ERK convergence.bioRxiv : the preprint server for biology · 2026Article
- Induction of stress granules alleviates programmed cell death induced by lysosomal damage during NK cell cryopreservation.Cell death discovery · 2026Article
- Regulatory complexity and therapeutic targeting of the necroptosis network.Frontiers in immunology · 2026Review
- PANoptosis and mitochondrial regulatory mechanisms in cerebral ischemia-reperfusion injury.Frontiers in physiology · 2026Review
- PANoptosis: a new perspective for targeting programmed cell death after spinal cord injury.Frontiers in immunology · 2026Review
- Spatial transcriptomic analysis identifies a necroptosis-prone thyroid follicular cell state in Hashimoto's thyroiditis.Frontiers in immunology · 2026Article
- Crosstalk of regulated cell death pathways in sepsis-associated acute kidney injury: implications for therapy.Frontiers in cell and developmental biology · 2026Review
- PTPN6/SHP-1 in autoimmune disease: immune tolerance, regulatory mechanisms, and therapeutic targeting.Frontiers in immunology · 2026Review
- A machine learning integrated multi-omics framework for risk prediction and target discovery in insomnia aggravated sepsis induced acute lung injury.Frontiers in immunology · 2026Article
- Liquid‒liquid phase separation: a potentially fundamental mechanism of sepsis.Cell death discovery · 2025Review
- Exploring PTPN6 as a dual oncogenic and immunological marker in melanoma.Discover oncology · 2025Article
- Multi-phase, multi-ethnic GWAS uncovers putative loci in predisposition to elite sprint and power performance, health and disease.Biology of sport · 2025Article
- Multi-omic analyses reveal PTPN6's impact on tumor immunity across various cancers.Scientific reports · 2025Article
- E2F2 induces microglial activation and augments depressive-like behavior in mice by repressing PTPN6 transcription.Cytotechnology · 2025Article
- Innate Immune Sensors and Cell Death-Frontiers Coordinating Homeostasis, Immunity, and Inflammation in Skin.Viruses · 2025Review
- Protein phosphatases in systemic autoimmunity.Immunometabolism (Cobham, Surrey) · 2025Review
- Article
- Effects ofCurrent issues in molecular biology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 10 institutions in 5 countries.
Mary SpeirDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Cameron J NowellMonash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-8662-9840
Alyce A ChenDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5018-8908
Joanne A O'DonnellWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Isaac S ShamieDepartment of Pediatrics, University of California San Diego, La Jolla, CA, USA.
Paul R LakinBiostatistics and Research Design Center, Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, USA.
Akshay A D'CruzDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2718-0673
Roman O BraunDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4352-3939
Jeff J BabonWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-5408-6239
Rowena S LewisWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Meghan Bliss-MoreauDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Inbar ShlomovitzDepartment of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shu WangDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Louise H CengiaWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Anca I StoicaDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Razq HakemPrincess Margaret Cancer Centre/University Health Network, University of Toronto, Toronto, Canada.
Michelle A KelliherDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, USA.
Lorraine A O'ReillyWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Heather PatsiourasLudwig Institute for Cancer Research, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Kate E LawlorCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-0471-6842
Edie WellerDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Nathan E LewisDepartment of Pediatrics, University of California San Diego, La Jolla, CA, USA.
Andrew W RobertsWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-7341-5720
Motti GerlicDepartment of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID http://orcid.org/0000-0001-9518-1833
Ben A CrokerDivision of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA. bcroker@health.ucsd.edu.ORCID http://orcid.org/0000-0002-0885-3599
Boston Children's Hospital · USThe University of Melbourne · AUTel Aviv University · ILHudson Institute of Medical Research · AUNovo Nordisk Foundation · DKThe Royal Melbourne Hospital · AUUniversity Health Network · CAUniversity of California San Diego · USUniversity of Massachusetts Chan Medical School · USWalter and Eliza Hall Institute of Medical Research · AU
Funding
Mechanism(s) of TAL-1/SCL-mediated LeukemogenesisR01CA096899 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI MICHELLE ALICE KELLIHER · 2004 to 2026
$6.9MRip Proteins in Innate Immune SignalingR01AI075118 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KELLIHER, MICHELLE ALICE · 2009 to 2024
$6.7MUnraveling the mammalian secretory pathway through systems biology and algorithm developmentR35GM119850 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LEWIS, NATHAN ENOCH · 2016 to 2025
$4.3MDefining the roles of RIPK1 and RIPK3 in emergency hematopoiesisR01HL124209 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CROKER, BEN ADAM · 2015 to 2019
$2.2MNCI NIH HHS R01 CA096899NHLBI NIH HHS R01 HL124209NIAID NIH HHS R01 AI075118NIGMS NIH HHS R35 GM119850
Abstract
Ptpn6 is a cytoplasmic phosphatase that functions to prevent autoimmune and interleukin-1 (IL-1) receptor-dependent, caspase-1-independent inflammatory disease. Conditional deletion of Ptpn6 in neutrophils (Ptpn6
Indexed as
AnimalsApoptosisCaspase 8Cells, CulturedGene DeletionInflammationInterleukin-1Interleukin-1alphaInterleukin-1betaMiceMice, Inbred C57BLMice, KnockoutNeutrophilsp38 Mitogen-Activated Protein KinasesProtein KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 6Caspase 8IL1B protein, mouseIL1R1 protein, mouseInterleukin-1Interleukin-1alphaInterleukin-1betaMLKL protein, mousep38 Mitogen-Activated Protein KinasesProtein KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 6Ptpn6 protein, mouseReceptor-Interacting Protein Serine-Threonine KinasesReceptors, Interleukin-1 Type IRipk1 protein, mouseRipk3 protein, mouseTumor Necrosis Factor-alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.